Rallybio (NASDAQ:RLYB) Stock Rating Lowered by Wall Street Zen

Rallybio (NASDAQ:RLYB – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Rallybio from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Rallybio has an average rating of “Sell”.

Read Our Latest Report on Rallybio

Rallybio Stock Performance

Shares of RLYB opened at $15.47 on Friday. The stock has a market capitalization of $83.23 million, a PE ratio of -4.22 and a beta of -0.73. The stock has a 50-day simple moving average of $32.44 and a 200-day simple moving average of $27.21. Rallybio has a 1 year low of $3.67 and a 1 year high of $17.57.

Rallybio shares are going to reverse split on the morning of Monday, November 23rd. The 1-2 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 19th.

Rallybio (NASDAQ:RLYB – Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($2.88) by $1.92. Rallybio had a negative return on equity of 31.44% and a negative net margin of 911.07%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of Rallybio in the 2nd quarter valued at approximately $1,155,000. ADAR1 Capital Management LLC boosted its position in shares of Rallybio by 4,411.1% during the 2nd quarter. ADAR1 Capital Management LLC now owns 926,352 shares of the company’s stock valued at $14,822,000 after purchasing an additional 905,817 shares in the last quarter. State Street Corp acquired a new position in shares of Rallybio in the 2nd quarter worth $208,000. Finally, BlackRock Inc. lifted its position in shares of Rallybio by 73.5% in the 2nd quarter. BlackRock Inc. now owns 30,332 shares of the company’s stock valued at $485,000 after acquiring an additional 12,846 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

About Rallybio

(Get Free Report)

Rallybio is a clinical-stage biotechnology company focused on developing treatments for people affected by rare and severe diseases. Founded in 2018, the company is based in New Haven, Connecticut, and has concentrated its research and development efforts on conditions with significant unmet medical needs. One of Rallybio’s investigational programs is RLYB212, an antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare condition that can cause dangerously low platelet counts in a fetus or newborn.

Read More

Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.